Drug
Drug
Periodic Safety Reporting for Ongoing Clinical Trials: IND Annual Reports, DSURs and EU CTR Annual Safety Reports
How IND annual reports, ICH E2F DSURs and EU CTR annual safety reports compare across FDA, EMA, MHRA and other regulators.
Drug
Drug-Induced Phospholipidosis in FDA and EMA Reviews: Nonclinical Assessment, Development Impact and Labeling
How FDA and EMA reviewers weigh drug-induced phospholipidosis findings, and when they have triggered a clinical hold, extra studies, monitoring, RMP entries or labeling.
Drug
FDA and EU GMP Expectations for Cloud-Hosted and SaaS Computerized Systems
FDA and EU GMP expectations for cloud and SaaS computerized systems: Annex 11, supplier qualification, data integrity and related 483 and warning-letter precedents.
Drug
EMA Environmental Risk Assessment for Generic and Hybrid Applications: Requirements and Precedents for Relying on Existing Data
How EMA applies ERA requirements to generic and hybrid applications, and when existing assessments, literature or exposure arguments can replace new studies.
Drug
CML Approval Endpoints: Molecular, Cytogenetic and Hematologic Responses Accepted by FDA and EMA
Primary endpoints and pivotal trial designs (MMR, CCyR, MCyR and hematologic response) behind FDA and EMA approvals of chronic myeloid leukemia therapies.
Drug
Body Composition Data in Obesity Drug Development: FDA and EMA Review of DXA and MRI Endpoints and Weight-Loss Efficacy Benchmarks
How FDA and EMA review DXA and MRI body-composition data in obesity drug programs, and the weight-loss efficacy benchmarks that still decide approval.
Drug
FDA Approvals Based on a Single Adequate and Well-Controlled Trial Plus Confirmatory Evidence
FDA approvals that rested on one adequate and well-controlled trial plus confirmatory evidence, and the types of supporting evidence reviewers accepted or rejected.
Drug
How FDA Weighs Nonclinical Toxicity Findings With No Clear Human Correlate
How FDA decides whether animal toxicity findings with no human correlate call for clinical monitoring, a clinical hold or labeling, with precedents from FDA reviews.
Drug
IND Safety Reporting Under 21 CFR 312.32: Sponsor Obligations, Aggregate Analysis, and Common Errors
Sponsor duties under 21 CFR 312.32: expedited 15- and 7-day reports, causality assessment, aggregate safety analysis, and common errors found in FDA inspections.
Drug
Substantial Modifications Under the EU Clinical Trials Regulation: Definition, CTIS Assessment and Grounds for Refusal
How the EU Clinical Trials Regulation defines substantial modifications, how CTIS assesses Part I and Part II changes, and common refusal grounds.
Drug
EMA Hybrid Applications Under Article 10(3): Data Requirements and Bridging Study Precedent
What EMA requires for Article 10(3) hybrid applications, and when CHMP has demanded bridging clinical or bioequivalence studies, drawn from EPAR precedent.
Drug
FDA Environmental Assessments and Categorical Exclusions Under 21 CFR Part 25 for Drug and Biologic Applications
How FDA applies 21 CFR Part 25 categorical exclusions to drug and biologic applications, and the precedents where it required a full environmental assessment.
Drug
Treatment-Free Remission and TKI Discontinuation in CML Labeling: FDA and EMA Approaches for Nilotinib
How FDA and EMA wrote treatment-free remission and TKI discontinuation into nilotinib's CML labeling, and the ENESTfreedom and ENESTop evidence behind it.
Drug
FDA Guidance for Weight-Reduction Drugs: Efficacy Benchmarks, Trial Duration and Safety Expectations
How FDA's draft obesity drug guidance has changed from 1996 to 2025, with its efficacy benchmarks, trial durations, estimands and safety exposure expectations.
Drug
AML Approval Endpoints at FDA and EMA: Complete Remission, Event-Free Survival and Overall Survival in Pivotal Trials
How FDA and EMA weigh complete remission, event-free survival and overall survival as AML approval endpoints, with pivotal trial precedents.
Drug
FDA's Rare Disease Evidence Principles and Evidentiary Flexibility for Ultra-Rare Disease Programs
How FDA's RDEP process works, plus single-trial approvals, external controls, surrogate endpoints and other evidence flexibility for rare disease programs.
Drug
FDA-Approved Drugs for Pediatric and Adolescent Obesity: Clinical Evidence and PREA Requirements
FDA-approved pediatric obesity drugs, the pivotal adolescent trials and BMI endpoints behind them, and how PREA waivers, deferrals and Written Requests shaped each approval.
Drug
FDA-Accepted Primary Endpoints and Pivotal Trial Designs in SLE and Lupus Nephritis Approvals
Primary endpoints, pivotal trial designs, and FDA reviewer views behind modern SLE and lupus nephritis approvals, from SRI-4 and BICLA to renal response composites.
Drug
FDA Endpoints and Noninferiority Margins for Antibacterial Approvals in cUTI and CABP
The primary endpoints, analysis populations and noninferiority margins FDA has accepted in cUTI and CABP antibacterial approvals, from guidance defaults to recent precedent.
Drug
Cardiovascular Outcomes Trials for Diabetes and Obesity Drugs: FDA and EMA Review of MACE Endpoints and Noninferiority Margins
How FDA and EMA reviewed CVOTs for diabetes and obesity drugs: accepted 3-point MACE definitions, the 1.8 and 1.3 noninferiority margins, and how results reached labeling.
Drug
FDA CMC and Impurity Questions for Synthetic Peptide ANDAs Referencing rDNA-Origin Liraglutide and Teriparatide
FDA guidance, product-specific guidances and review records on CMC, impurity and immunogenicity questions for synthetic generic peptides referencing liraglutide and teriparatide.
Drug
CMC Readiness Issues at FDA End-of-Phase 2 and Pre-NDA/Pre-BLA Meetings
The CMC gaps FDA raises at End-of-Phase 2 and pre-NDA/pre-BLA meetings, and how they changed submission timing, content and review outcomes.
Drug
FDA Refuse-to-File Letters for NDAs and BLAs: Common Deficiencies and Resubmission Strategies
The deficiencies behind past FDA refuse-to-file letters for NDAs and BLAs, grouped by type, and what sponsors changed to get resubmissions accepted.
Drug
FDA Primary Endpoints and Trial Designs in Pulmonary Arterial Hypertension Approvals
FDA precedent on PAH primary endpoints and trial designs: six-minute walk distance, clinical worsening, morbidity/mortality outcomes and hemodynamics across approvals.
Drug
Container Closure Changes Under the EU Variations Regulation: Type IA, IB and II Classification and EMA Data Expectations
How EU container closure changes are classified as Type IA, IB or II under Regulation 1234/2008, and the stability and packaging data EMA expects.
Drug
FDA Expectations for INDs Combining Two Investigational Oncology Agents: Contribution of Components and Dose Finding
What FDA expects in INDs pairing two investigational cancer drugs: codevelopment criteria, contribution-of-components evidence, nonclinical support, and combination dose-finding designs.
Drug
MMRM, Missing Data and Estimands in FDA Statistical Reviews of NDAs and BLAs
How FDA statistical reviewers assess MMRM, missing-data sensitivity analyses and ICH E9(R1) estimands in NDA and BLA reviews, with named application examples.
Drug
How FDA Evaluates Recall Periods for Patient-Reported Symptom Outcomes: 24-Hour, 7-Day, and Daily Diary Designs
How FDA has judged 24-hour, 7-day and daily diary recall periods for PRO symptom measures, drawing on COA reviews, guidance and approved labeling.
Drug
New Active Substance Status at EMA and MHRA: Assessment Criteria and Evidence Standards
How EMA and MHRA test new active substance claims, including therapeutic-moiety analysis, the Article 10(2)(b) presumption, and the evidence CHMP has accepted or rejected.
Drug
Nonclinical PK and Toxicokinetic Data Required Before First-in-Human Small-Molecule Trials Under ICH M3(R2) and S3A
The nonclinical PK, protein binding, metabolism and toxicokinetic data FDA expects before first-in-human small-molecule dosing under ICH M3(R2) and S3A.
Drug
EMA Conditional Marketing Authorisations Based on Surrogate and Intermediate Endpoints: Precedents and Specific Obligations
EMA conditional approvals granted on surrogate or intermediate endpoints, the Annex II.E specific obligations attached, and which products converted or were withdrawn.
Drug
Comparative Claims and Secondary Endpoints in the Clinical Studies Section of FDA Prescribing Information
What evidence FDA requires for superiority and comparative claims in Section 14, and how reviewers have handled labeling claims based on secondary endpoints.
Drug
Limitations of Use Statements in FDA Prescribing Information: Legal Basis and Review Precedents
How FDA adds, narrows, and removes Limitations of Use in drug labels: the 21 CFR 201.57 basis, guidance drafting rules, and review precedents.
Drug
FDA Requirements for CYP3A and Transporter Drug Interaction Studies and Labeling in Recent NDA Clinical Pharmacology Reviews
How FDA reviewers assess CYP3A and transporter interactions in recent NDAs: required clinical studies, PBPK acceptance, labeling language, and postmarketing requirements.
Drug
FDA Postmarketing Requirements for Pregnancy Registries, Lactation Studies, and PLLR Labeling in Recent Approvals
How FDA has used 505(o)(3) pregnancy registries, lactation studies, and PLLR-format labeling as postmarketing requirements in drug and biologic approvals from 2023 to 2026.
Drug
FDA Nitrosamine Impurity Requirements in NDA, ANDA, and Supplement Reviews
How FDA reviewers assess nitrosamine risk in NDAs, ANDAs, and supplements: risk assessments, CPCA-based acceptable intake limits, and the control strategies FDA expects.
Drug
FDA Review of Shelf-Life Extrapolation and Stability Statistics Under ICH Q1E
How FDA reviewers apply ICH Q1E to stability regression, batch poolability, and shelf-life extrapolation in NDA and BLA reviews, with named examples.
Drug
How Comparability Protocols, ICH Q12 Established Conditions, and PACMPs Lower FDA Post-Approval Reporting Categories
How comparability protocols, PACMPs, and ICH Q12 established conditions shift CMC changes into lower FDA reporting categories, with examples from approved applications.
Drug
FDA Reporting Categories for Manufacturing Site Transfers and Additions: PAS vs CBE-30 for NDAs and BLAs
How FDA assigns PAS, CBE-30, or annual-report categories to NDA and BLA manufacturing site changes, and the supporting data it expects for each.
Drug
Sponsor Oversight of CROs and Vendors: FDA BIMO and EMA GCP Inspection Findings
FDA BIMO and EMA GCP inspection findings on sponsor oversight of CROs and vendors, with the recurring deficiencies set against ICH E6(R3) expectations.
Drug
Sponsor Oversight of Decentralized Trial Elements: FDA BIMO Findings and Guidance Expectations
FDA BIMO and warning-letter findings on vendor eCOA data, home-dosed product, virtual visits, and remote consent, compared against current DCT and ICH E6(R3) guidance.
Drug
Environmental Monitoring in ISO 5/Grade A Aseptic Areas: Common FDA Warning Letter and Form 483 Citations
The environmental monitoring failures FDA repeatedly cites in ISO 5/Grade A aseptic areas, covering limits, excursion investigations, personnel monitoring and EM data integrity.
Drug
Media Fill Deficiencies in FDA 483s and Warning Letters: Common Citations and Expected Corrective Actions
The media fill deficiencies FDA repeatedly cites at sterile drug and biologic manufacturers, and the corrective actions its 483s and warning letters ask for.
Drug
FDA Approvals Based on Natural-History and External Controls: What Reviewers Accepted
Which FDA approvals rested on natural-history or external controls, and the control features reviewers treated as adequate or uninterpretable.
Drug
FDA Complete Response Letters Citing Inadequate External or Historical Controls
FDA complete response letters that rejected natural history, registry, or literature-based controls, with the deficiencies FDA cited and what it asked sponsors for.
Drug
Broad Orphan Drug Designation with Subtype-Limited Rare Pediatric Disease Designation: FDA Precedents
FDA precedents where orphan designation covered a broad disease but rare pediatric disease designation covered only a subtype, and how voucher decisions turned out.
Drug
Arguing Significant Benefit Before the COMP When an Authorised EU Treatment Already Exists
How sponsors have argued significant benefit to EMA's COMP against authorised alternatives, and which clinical-advantage and patient-care arguments succeeded or failed.
Drug
How Sponsors Calculated Prevalence for FDA Orphan Drug Designation and Where FDA Pushed Back
The prevalence methods sponsors of approved rare-disease drugs used for FDA orphan designation, and the population definitions that drew OOPD questions or revocations.
Drug
PREA's Orphan Exemption and the RACE Act: Pediatric Study Plans for Orphan Oncology Programs
When orphan oncology drugs still need a pediatric study plan under the RACE Act, with examples from recent FDA approval packages.
Drug
Atopic Dermatitis Endpoints in FDA Approvals Since 2017: IGA 0/1, EASI-75 and Itch NRS in Systemic vs Topical Products
The primary and key secondary endpoints behind FDA atopic dermatitis approvals since 2017, with systemic and topical products compared on IGA 0/1, EASI-75 and itch NRS.
Drug
Itch, Pain and Quality-of-Life Claims in FDA Dermatology Drug Labeling
How FDA reviewers treated itch, pain and quality-of-life PRO claims in dermatology labels, and why broad QoL instruments rarely reach Section 14.
Drug
Alopecia Areata Approvals: SALT Endpoints, Scalp-Coverage Thresholds and Patient-Reported Hair Outcomes at FDA and EMA
The SALT thresholds, assessment timepoints and patient-reported hair outcomes behind FDA and EMA alopecia areata approvals, and where the two agencies differed.
Drug
Vehicle-Controlled Pivotal Trial Design for Novel Topical Dermatology Drugs: Roflumilast, Ruxolitinib and Tapinarof Creams
How Zoryve, Vtama and Opzelura structured their vehicle-controlled Phase 3 trials, and what FDA reviewers questioned on missing data, endpoints and exposure.
Drug
Topical 505(b)(2) Reformulations at FDA: Pathway Criteria, Systemic Exposure Bridging and Local Efficacy
When topical reformulations take the 505(b)(2) route, how recent FDA reviews bridged systemic exposure to the listed drug, and why local efficacy still came from the applicant's own trials.
Drug
PREA Pediatric Requirements in Recent FDA Dermatology Approvals
How FDA applied PREA waivers, deferrals and pediatric postmarketing requirements across selected dermatology drug and biologic approvals from 2022 to 2026.
Drug
Integrated vs Standalone ICH S7A Safety Pharmacology in FDA-Approved Small-Molecule NMEs: Oncology vs Non-Oncology Precedents
How often FDA-approved small-molecule NMEs built ICH S7A core-battery endpoints into repeat-dose toxicology studies versus standalone studies, comparing oncology and non-oncology programs.
Drug
New Approach Methodologies in FDA Novel Drug and Biologic Approvals, 2022–2026
How FDA novel drug and biologic approvals from 2022 to 2026 used NAMs and weight-of-evidence waivers, by therapeutic area and modality.
Drug
Cardiac Safety Pharmacology for New Drugs: How FDA Assessed QT Risk from hERG to Postmarketing (2023–2026)
Across 94 new small-molecule drugs approved 2023–2026: hERG margins, telemetry, TQT vs concentration-QTc, and how often a nonclinical QT signal predicted the clinic.
Drug
FDA Complete Response Letter: What It Is and What Happens Next
What an FDA Complete Response Letter is, what it contains, and the regulatory steps and timelines a sponsor must navigate after receiving one.
Drug
Orphan Drug Designation: Incentives and FDA Refusal Grounds
Orphan drug designation explained: the US criteria, sponsor benefits including exclusivity, and grounds for FDA denial.
Drug
Fast Track vs Breakthrough Therapy vs RMAT vs Priority Review vs National Priority Voucher
How Fast Track, Breakthrough Therapy, RMAT, Priority Review, and FDA's National Priority Voucher pilot change review in practice, with approval precedents.
Drug
Why FDA Issues Complete Response Letters: Recurring Deficiencies
The deficiency categories FDA cites most often in Complete Response Letters, and the specific findings that recur across NDAs, BLAs, and ANDAs.
Drug
Breakthrough Therapy Designation Since 2020: Review Outcomes and the National Priority Voucher
Notable FDA approvals with Breakthrough Therapy Designation since 2020, how BTD affected priority review and review cycles, and how it compares with the National Priority Voucher.
Drug
GLP-1 Receptor Agonists and Incretin Therapies: Recent FDA and EMA Approvals and the Clinical Pipeline
Recent FDA and EMA approvals of GLP-1 and incretin therapies, including oral orforglipron and semaglutide, plus the late-stage multi-agonist clinical pipeline.
Drug
FDA Endpoint Selection, Composite Endpoints, and Biomarkers in Ultra-Rare Disease Trials
How FDA has decided endpoint selection, composite endpoints, and biomarker evidence in ultra-rare disease trials with heterogeneous populations.
Drug
Trial Injections, System Suitability, and Audit Trails in FDA 483s and Warning Letters
How FDA 483s and warning letters treat trial and unreported chromatography injections, and the system-suitability and audit-trail controls FDA accepts.
Drug
FDA and EMA Endpoints and Pivotal Trial Designs for Endometriosis-Associated Pain Drugs
Pivotal trial designs, pain endpoints, and responder definitions behind FDA endometriosis-pain approvals, compared with EMA authorizations and indication restrictions.
Drug
FDA Precedents for Removing or Narrowing Boxed Warnings and the Supporting Postmarketing Evidence
Documented cases where FDA removed or narrowed boxed warnings, grouped by the postmarketing trials, epidemiology, and class-wide reviews behind each change.
Drug
FDA-Accepted Efficacy Endpoints in Acute Pain Trials: SPID, Time to Rescue, and Rescue Analgesia Handling
Which efficacy endpoints FDA has accepted in acute pain trials, including SPID, time to rescue and rescue use, and how reviewers handle post-rescue pain scores.
Drug
Oral SERDs for ER-Positive, HER2-Negative Advanced Breast Cancer: FDA and EMA Approvals, Efficacy and Safety
FDA and EMA approvals of oral SERDs for ESR1-mutated ER+/HER2- advanced breast cancer, with review findings on monotherapy and CDK4/6 combinations.
Drug
New Drug Marketing Authorization Compared: FDA, Health Canada, MHRA and EMA
Compares new-drug pathways, CTD dossier requirements, review timelines and expedited routes at FDA, Health Canada, MHRA and EMA.
Drug
First-in-Class Mechanisms and Notable Oncology Approvals at FDA and EMA, 2025–2026
FDA and EMA first-in-class and notable oncology approvals from September 2025 to September 2026, with the mechanism, pathway and pivotal evidence for each.
Drug
FDA's Animal Rule: CBRN Approvals and Their Evidence Base
Every FDA Animal Rule approval for CBRN countermeasures, with the animal efficacy studies, human safety data, and PK bridges behind each.
Drug
How FDA Cites 21 CFR 211.192: Inadequate Deviation, OOS, and Yield-Discrepancy Investigations
How FDA applies 21 CFR 211.192 in 483s and warning letters to OOS, deviation, and yield-discrepancy investigations, and what it treats as adequate.
Drug
Labeling Carve-Outs for Generic and 505(b)(2) Products
How FDA applies the same-labeling rule and its exceptions when generic and 505(b)(2) applicants omit protected indications, with the governing precedents.
Drug
Bioequivalence Evidence for Generic Nasal Sprays and Orally Inhaled Products: FDA vs. EMA
How FDA and EMA assess bioequivalence for locally acting nasal sprays and orally inhaled products, and where their evidence frameworks diverge.
Drug
Efficacy Endpoints FDA Has Accepted for Outpatient COVID-19 and Respiratory Antivirals
Which clinical endpoints FDA accepted for outpatient COVID-19, influenza, and RSV antivirals, and how virologic data was weighed against clinical benefit.
Drug
Process Parameters and Set Points Across Manufacturing Sites: FDA and EMA Expectations
How FDA and EMA assess process parameter and set point differences between manufacturing sites, and the comparability and validation evidence each expects.
Drug
FDA-Accepted Endpoints And Trial Designs For Supportive-Care Oncology Indications
FDA-accepted primary endpoints, scoring scales, and pivotal trial designs for oral mucositis, CINV, and febrile neutropenia products.
Drug
Post-Approval Prescribing-Information Changes: PAS vs. CBE and SPL Submission Expectations
How FDA routes post-approval labeling changes across prior-approval supplements, CBE-30, CBE-0, and annual reports, plus the SPL expectations attached to each.
Drug
FDA-Accepted Primary Endpoints and Comparator Arm Designs in NSCLC Trials
How the FDA's accepted primary endpoints and comparator arms in NSCLC trials vary by line of therapy, drug mechanism, and approval pathway.
Drug
FDA Responses to Data Falsification and Fraud: The Application Integrity Policy and Enforcement Precedents
How the FDA acts on data falsification and fraud, what the Application Integrity Policy triggers, and the enforcement precedents that follow.
Drug
When the FDA Expects Food-Effect Studies: Timing, Design, and Review Precedents
When the FDA expects food-effect studies in drug development, the study design it recommends, waiver criteria, and what review precedents show.
Drug
FDA-Accepted Endpoints and Trial Designs for Urate-Lowering Therapies in Gout
How FDA-approved gout urate-lowering therapies were designed — serum urate endpoints, thresholds, comparators, and trial duration by program.
Drug
FDA Precedents for Approving on a Pre-Specified Interim Analysis of the Primary Endpoint
How the FDA treats pre-specified interim analyses of the primary endpoint, with the statistical safeguards and concrete approvals that relied on them.
Drug
FDA-Accepted Efficacy Endpoints in Autism Spectrum Disorder Drug Trials
How the FDA's approved and reviewed autism drug programs define acceptable efficacy endpoints, rating scales, and indications.
Drug
FDA Precedents for Drugs in Ultra-Rare and Small-Population Pediatric Cancers
How FDA has handled trial design, endpoints, and confirmatory evidence for drugs in ultra-rare and small-population pediatric cancers.
Drug
Recurring Safety and Toxicity Findings in FDA Reviews of GLP-1 Receptor Agonists
How FDA reviews and labeling treat the recurring nonclinical and clinical safety signals shared across GLP-1 receptor agonists.
Drug
Recall vs. Market Withdrawal vs. Stock Recovery: How FDA Classifies Corrective Actions and What Must Be Reported
How FDA distinguishes recalls from market withdrawals and stock recoveries under 21 CFR Part 7, and what triggers a mandatory report.
Drug
FDA New Approach Methodologies (NAMs): Regulatory Pathways for Alternatives to Animal Testing in Drug and Biologic Programs
FDA's 2025–2026 NAM guidances explained: accepted methods, validation standards, and submission requirements for drug and biologic programs.
Drug
FDA 180-Day Generic Exclusivity: Mechanics, Forfeiture, and Shared Exclusivity in Recent First-Generic ANDA Approvals
How FDA's 180-day generic exclusivity is earned, triggered, forfeited, and shared, illustrated by recent first-generic ANDA approvals.
Drug
FDA BIMO Inspection Findings: Common Form 483 and Warning-Letter Citations for Clinical Investigators, Sponsors, and CROs
The most-cited FDA BIMO Form 483 and warning-letter findings for clinical investigators, sponsors, and CROs, with the underlying CFR provisions.
Drug
FDA-Accepted Endpoints for Osteoarthritis: Symptomatic Relief Versus Structure Modification
FDA-accepted endpoints for osteoarthritis symptomatic and structure-modification claims, covering approved precedents and current guidance.
Drug
Basket, Umbrella, and Platform Trials: FDA Guidance Definitions and Design Expectations by Master-Protocol Type
FDA definitions, design expectations, and regulatory requirements for basket, umbrella, and platform master-protocol trial types across key guidance documents.
Drug
Post-Approval Dosing Regimen Changes at FDA and EMA: Evidence Standards for Label Updates
How FDA and EMA evaluate post-approval dosing changes, and what clinical or modeling evidence has supported those label updates.
Drug
FDA and ICH Stability Program Requirements: Ongoing Studies, Bracketing and Matrixing, Reduced Sampling, and Common Citation Patterns
FDA and ICH requirements for ongoing stability programs, bracketing and matrixing, reduced sampling, and how program deficiencies are cited in 483s and warning letters.
Drug
IMP Labeling Requirements: FDA 21 CFR 312 Versus EU Clinical Trials Regulation and GMP Annex 13
FDA 21 CFR 312 versus EU CTR and GMP Annex 13 IMP labeling requirements compared, with key differences for dual-jurisdiction trials.
Drug
Container Closure System Deficiencies in FDA NDA and BLA Reviews: Recurring Themes and Evolving Expectations Since 1999
Recurring FDA container closure system deficiencies in NDA/BLA reviews and inspections, and how expectations have evolved since the 1999 guidance.
Drug
FDA Project Optimus vs EMA: Diverging Expectations for Phase 1 Oncology Dose Escalation and Optimization
How FDA Project Optimus and EMA diverge on phase 1 oncology dose escalation and optimization, with agency precedents and practical implications.
Drug
FDA Approvals Based on Prespecified Subgroup Results After a Failed Overall Trial
How FDA treats prespecified subgroup wins when the overall pivotal trial fails, drawn from approval precedents and Complete Response Letters.
Drug
How FDA Assesses Drug-Induced Liver Injury: Hy's Law, eDISH, and Liver-Safety Monitoring Expectations
How FDA evaluates DILI risk: Hy's Law criteria, eDISH screening, liver-safety monitoring expectations, and hepatotoxicity findings in CRLs and labeling.
Drug
How FDA Facility Inspection Outcomes Shape NDA and BLA Approvals
How Form 483 observations, OAI classifications, and facility withholds convert into Complete Response Letters and delayed NDA and BLA approvals.
Drug
FDA Pre-Approval Inspections: Timing After NDA/BLA Submission and How Facilities Are Selected
How FDA times pre-approval inspections during NDA/BLA review and the risk factors that determine which manufacturing facilities get inspected.
Drug
FDA Drug Approvals Targeting GPCR Mechanisms, 2021 to 2026
GPCR-targeted drugs the FDA approved from 2021 to mid-2026, with receptor targets, receptor classes, and therapeutic areas.
Drug
Population Pharmacokinetics in NDA and BLA Submissions: FDA Expectations and Labeling Impact
FDA's expectations for popPK in NDA and BLA filings, with approved-drug examples where the analysis shaped Specific Populations, dosing, and pediatric labeling.
Drug
Pediatric and Neonatal Drug Trials: FDA Requirements Under PREA and Pediatric Study Plans
How FDA's PREA and BPCA requirements, pediatric study plans, and subpart D ethical protections govern drug trials in children and neonates.
Drug
Starting a First-in-Human Trial: FDA IND, China NMPA, and Australia CTN/CTX Compared
Compares FDA IND, China NMPA, and Australia CTN/CTX requirements for authorizing a first-in-human trial — documentation and timelines side by side.
Drug
Common FDA 483 and Warning-Letter Observations in Aseptic Fill-Finish, Mapped to EU GMP Annex 1
The recurring FDA 483 and warning-letter observations against aseptic fill-finish operations, mapped to their EU GMP Annex 1 counterparts.
Drug
Recent FDA Approvals of Non-Opioid Analgesics: Mechanisms, Indications, and Pivotal Evidence
Recent FDA-approved non-opioid analgesics, their mechanisms of action, approved indications, and the pivotal evidence supporting each.
Drug
cGMP for Radiopharmaceuticals and Radionuclides in Late-Phase Trials: Short Half-Lives and Dosimetry
How FDA cGMP rules govern radiopharmaceutical manufacturing in late-phase trials, including short half-life release testing and dosimetry.
Drug
U.S. Representation in Multiregional Trials: FDA Approval Trends
Whether FDA is hardening US enrollment requirements in oncology MRCTs—via 21 CFR 312.120, the Sept 2024 draft MRCT guidance, ICH E17, and CRL precedents.
Drug
COA and PRO Instruments in FDA GLP-1 Obesity and CV Programs
COA and PRO instruments found in FDA labeling and clinical reviews for GLP-1 obesity and cardiovascular outcome programs, with regulatory context.
Drug
FDA Guidance on AI/ML Use in Clinical Trial Data Analysis
FDA's views on AI/ML in clinical trial data analysis, from January 2025 drug/device draft guidances and frameworks on model credibility and bias controls.
Drug
FDA Labeling and CMC Issues on Daptomycin Products, 2021–2026
Key FDA labeling and CMC deficiencies raised on daptomycin NDAs and ANDAs from 2021 to 2026, covering impurities, sterility, stability, and labeling.
Drug
US ORR-Based Oncology Approvals, DoR Under 6 Months: 2021–2026
FDA oncology approvals (July 2021–2026) where ORR was the primary efficacy basis and median duration of response in pivotal population was under 6 months.
Drug
Phase 1, 2, and 3 Clinical Trials: FDA Definitions to Advance
FDA's definitions of Phase 1, 2, and 3 trials and the procedural and substantive requirements sponsors must meet to advance between them.
Drug
FDA 483s, Warning Letters, and Import Alerts: How They Escalate
Definitions, legal distinctions, and real escalation pathways among FDA's three core enforcement instruments: Form 483, warning letter, and import alert.
Drug
GMP Basics and When FDA Expects Compliance: Enforcement Lessons
What GMP requires, when FDA enforcement says it applies, and what early-stage manufacturers have actually been cited for.
Drug
IND Applications: FDA Expectations and Clinical Hold Triggers
IND requirements, FDA expectations by phase, and the specific deficiencies that have triggered clinical holds — drawn from the governing regulations.
Drug
NDA, BLA, or ANDA: Choosing the Right Marketing Pathway
Which FDA marketing application — NDA, BLA, or ANDA — applies to your product, and how the three pathways differ in evidence, exclusivity, and process.
Drug
Accelerated Approval: Framework and Failed Confirmatory Trials
How accelerated approval works under FDA statute, and what has happened in practice when confirmatory trials failed to validate the surrogate endpoint.
Drug
Drug Master Files and Letters of Authorization: What FDA Expects
What a Drug Master File is, how suppliers authorize client references, and what FDA guidance requires for DMF content and letters of authorization.
Drug
REMS Programs: Safety Findings That Trigger an FDA Requirement
REMS definition, legal authority under FDAAA, and the safety findings and risk criteria that lead FDA to require one.
Drug
Meeting Pathways: FDA, EMA, MHRA, Health Canada, PMDA, NMPA
A side-by-side comparison of formal regulatory meeting pathways across FDA, EMA, MHRA, Health Canada, PMDA, and NMPA, including types, triggers, and timelines.
Drug
FDA Data-Integrity Failures and 21 CFR Part 11 Spreadsheets
FDA's most-cited data-integrity failures in warning letters and why spreadsheet-based records cannot meet 21 CFR Part 11 requirements.
Drug
Drug Master Files: FDA, EMA, PMDA, Health Canada, TGA Compared
Side-by-side comparison of DMF systems at FDA, EMA, PMDA, Health Canada, and TGA—covering registration, structure, access procedures, and fees.
Drug
Converting a Protocol Into a Master Protocol Under an Active IND
FDA's regulatory framework for converting or restructuring an existing protocol into a master protocol under an active IND.
Drug
Digital Trial Recruitment Ads: FDA, Health Canada, IRB/REB
FDA and Health Canada rules for digital clinical-trial recruitment ads: permissible content, IRB/REB review, and tracking pixel considerations.
Drug
FDA Drug Repurposing to a New Indication With Phase 2 Data
How FDA credits prior Phase 2 data in drug repurposing programs, covering 505(b)(2) applications, efficacy supplements, and substantial-evidence standards.
Drug
Minimal Residual Disease (MRD) as an FDA Endpoint or Evidence
Where and how FDA has accepted MRD as a primary endpoint or supportive evidence across hematologic malignancy approvals.
Drug
FDA Boxed Warnings: Evidence Patterns Behind Labeling Action
How FDA justifies boxed warnings by evidence type — trial data, meta-analyses, animal studies, and post-market reports — with product examples.
Drug
FDA 483 Observations by Frequency and Quality-System Subsystem
FDA 483 observations ranked by frequency and mapped to CGMP and QSIT quality-system subsystems, with the CFR provisions most often cited.
Drug
FDA and ICH on Fish Embryo Assays for Embryo-Fetal Studies
FDA and ICH regulatory standing of fish embryo assays as alternatives or adjuncts to standard mammalian embryo-fetal development studies.
Drug
FDA Nonclinical Expectations for Veterinary or Ex-US Compounds
FDA nonclinical requirements when a veterinary or ex-US approved compound enters US human development, including gap analysis and bridging strategy.
Drug
FDA Rules for Oral Liquid Dosing Devices and Dosing Errors
FDA's oral liquid dosing-device requirements explained alongside the pediatric dosing errors and labeling problems that shaped them.
Drug
ANDA Guidance and Approvals for First-Time Generics Sponsors
Key FDA requirements and approval patterns for bioequivalence, CMC, patent certification, and submission mechanics in a first ANDA filing.
Drug
FDA Peptide Approvals and Guidance: The Regulatory Path
FDA peptide approvals, generic pathways, and guidance examined to clarify clinical pharmacology and regulatory expectations for peptide developers.
Drug
Effective FDA Briefing Books: What Review Divisions Want
What separates FDA briefing books that drive decisions from those that stall programs — drawn from review division meeting minutes and correspondence.
Drug
ICH E3 Statistical Methods in CSRs and EU CTIS Practice
ICH E3 requirements for the CSR statistical methods section and how EU CTIS sponsors structure it, including Appendix 16.1.9 cross-referencing practice.
Drug
FDA Requirements for First-in-Human Oncology IND Trials
FDA's nonclinical requirements, starting-dose justification, dose-escalation standards, and clinical hold triggers for first-in-human oncology INDs.
Drug
Psychedelic Trial Design: Blinding, Endpoints, and FDA on MDMA
Blinding strategies, comparator arms, and endpoints in real psychedelic trial records, plus FDA's design concerns from the Lykos MDMA review.
Drug
FDA Post-Approval Changes: Annual Report, CBE-30, or PAS
How sponsors classify post-approval manufacturing changes across FDA reporting tiers, with real examples of Agency disagreements on category selection.
Drug
EMA CHMP Qualification of Novel Methodologies and Biomarkers
How the EMA qualifies novel biomarkers, outcome assessments, and models, and what a qualification opinion or letter of support signals to sponsors.
Drug
FDA-Approved Drugs for Obstructive Hypertrophic Cardiomyopathy
FDA-approved oHCM drug therapies, with the pivotal endpoints, trial designs, labeling restrictions, and REMS behind each approval.
Drug
China's NMPA Conditional Approval Pathway for Oncology Products
How China's NMPA applies conditional approval in oncology: eligibility, evidence standards, post-approval commitments, and the products granted it.
Drug
FDA Guidance for Inflammatory Bowel Disease Drug Development
How FDA guidances shape endpoints, trial design, and efficacy standards for ulcerative colitis, Crohn's disease, and pediatric IBD drugs.
Drug
Prodrug Strength in FDA Labeling: Active Moiety vs. Prodrug
How FDA has expressed prodrug strength in labeling — as active-moiety equivalents versus the prodrug itself — and the approved precedents on each side.
Drug
Phase I Transparency Under the EU Clinical Trials Regulation
Which Phase I trial documents CTIS publishes, on what timelines, and how sponsors use deferral and redaction to manage disclosure.
Drug
Recent ANDA Approvals: FDA's Newest Generic Drug Clearances
A structured look at FDA's most recent ANDA approvals — active ingredients, dosage forms, and first-generic milestones.
Drug
ICH E6(R3) vs. E6(R2): Changes to Sponsor Responsibilities
ICH E6(R2) vs. E6(R3) sponsor obligations: quality management, risk-proportionate monitoring, digital data governance, and service-provider oversight.
Drug
FDA-Approved Second-Line Therapies for Hepatocellular Carcinoma
FDA-approved second-line therapies for advanced HCC after sorafenib: regorafenib, cabozantinib, ramucirumab, pembrolizumab, and nivolumab, with indications.
Drug
Primary Endpoints for Phase 3 Huntington's Disease Trials
Phase 3 primary endpoints accepted by FDA and EMA for Huntington's disease trials, covering approved chorea therapies and registered disease-modifying programs.
Drug
Phase 2 Endpoints in Recurrent/Metastatic HNSCC Trials
Primary endpoints used in Phase 2 R/M HNSCC trials and their regulatory acceptability for accelerated or traditional approval under FDA and EMA frameworks.
Drug
FDA Feedback in Pre-IND Type B Meetings for Solid Tumors
FDA feedback from pre-IND Type B meetings for solid tumor programs, covering nonclinical adequacy, dose selection, CMC, trial design, and biomarkers.
Drug
Ozempic (Semaglutide) Prescribing Information Changes Since 2022
All FDA-approved labeling supplements for Ozempic (semaglutide, NDA 209637) since 2022, covering new indications, safety updates, and pen/packaging changes.
Drug
Real-World Evidence in FDA Prescribing Information Labeling
Which FDA-approved drugs include real-world data in their labeling, and what methodological standards determine whether RWD/RWE qualifies.
Drug
Patient-Reported Outcomes in CDER Prescribing Information
How CDER has incorporated PRO instruments into approved prescribing information from 2021–2026, by therapeutic area, instrument, and labeling section.
Device
Device
FDA-Authorized Vagus Nerve Stimulation Devices: Indications, Regulatory Pathways, and Pivotal Evidence
FDA-authorized vagus nerve stimulation devices by PMA, De Novo, and 510(k): indications, decision dates, and the pivotal clinical evidence behind each.
Device
Clinical Study Designs and Accuracy Criteria Behind FDA Authorizations of Continuous Glucose Monitors
How FDA evaluates continuous glucose monitor accuracy: pivotal study designs, MARD and point-accuracy metrics, iCGM special controls, and device-level results from authorizations.
Device
FDA Regulation of Consumer Infant Monitors: General Wellness vs. Medical Device Claims
How FDA regulates consumer infant monitors tracking SpO2, pulse, and breathing, from Owlet enforcement to the QYU over-the-counter pathway and the line between wellness and device claims.
Device
FDA-Authorized Non-Invasive Neuromodulation Devices for Migraine and Cluster Headache: Pathways, Indications and Clinical Evidence
How FDA authorized non-invasive neuromodulation devices for migraine and cluster headache: De Novo and 510(k) pathways, indications, OTC status, and pivotal trial evidence.
Device
Implantable Neurostimulators Under FDA PMA: Approval Pathways and Indication Expansion for SCS, DBS, and Sacral Neuromodulation
How FDA approved spinal cord, deep brain, and sacral neuromodulation devices through original PMAs and expanded their indications through PMA supplements.
Device
FDA Computer Software Assurance vs. Traditional Computer System Validation: Changed Expectations and Inspection Findings
How FDA's Computer Software Assurance guidance differs from traditional computer system validation, and how warning letters and 483s treat software validation failures.
Device
Over-the-Counter CGM Clearance: FDA 510(k) Pathway and Differences From Prescription iCGMs
How FDA cleared Stelo, Lingo, and Libre Rio as OTC iCGMs via 510(k), and how their product codes, populations, and controls differ from prescription iCGMs.
Device
FDA Authorization of Automated Insulin Delivery Systems: iCGM, ACE Pumps, iAGC Controllers and Supporting Clinical Evidence
How FDA classifies and authorizes iCGMs, ACE insulin pumps and iAGC algorithms, and the clinical evidence behind each De Novo, PMA and 510(k) decision.
Device
FDA Pulse Oximeter Accuracy Across Skin Pigmentation: Guidance and 510(k) Clearance Expectations
How FDA's pulse oximeter accuracy expectations for skin pigmentation have changed from the 2013 510(k) guidance to the 2025 draft, and how recent clearances reflect them.
Device
FDA Pediatric Indications for Medical Devices: Extrapolation, Incentives and Precedents
How FDA defines pediatric device populations, extrapolates adult data, rewards pediatric development, and has applied these policies in PMA, De Novo, 510(k) and HDE decisions.
Device
FDA Medical Device Cybersecurity Under Section 524B: Premarket Requirements, SBOMs, and Enforcement Findings
What section 524B requires in cyber device premarket submissions, including SBOMs and unsupported components, and what FDA warning letters and 483s have cited.
Device
Material and Supplier Changes to 510(k)-Cleared Devices: New 510(k) Triggers and FDA Testing Expectations
When a material or supplier change to a 510(k)-cleared device triggers a new 510(k), and the biocompatibility and performance testing FDA expects.
Device
FDA Review Timelines by Pathway and Product Type: Actual Submission-to-Decision Data
Actual FDA submission-to-decision times for NDAs, BLAs, biosimilars, resubmissions, CNPV approvals, 510(k)s and De Novos, compared against user-fee goals.
Device
FDA Review of Multiple Function Device Products: Policy Framework and 510(k) and De Novo Precedents
How FDA scopes premarket review for devices that combine several functions, with 510(k) and De Novo precedents showing how multi-function products were cleared or granted.
Device
Accelerated Aging Versus Real-Time Stability Data for Device Shelf-Life Claims
How FDA weighs accelerated aging against real-time data for device shelf-life and storage claims in 510(k) and De Novo review.
Device
Software Failure Probability in Device Risk Analysis: FDA's Position Under ISO 14971 and the Premarket Software Guidance
Why FDA treats software failures as systematic rather than probabilistic, how that squares with ISO 14971, and what 510(k) and De Novo decisions show.
Device
The 510(k) Review Process: From eSTAR Submission To Substantial Equivalence Decision
The four stages of FDA 510(k) review — eSTAR, RTA screening, substantive review, and AI holds — with MDUFA V timelines for each.
Device
Adding A Mobile App Or BYOD Platform To A Class III Device: FDA Submission Type And PMA Supplement Precedents
Which PMA supplement type FDA expects when an app or BYOD platform is added to a Class III device, and the approval precedents.
Device
FDA Authorization of OTC and Home-Use Diagnostic Tests: Pathways, Precedents, and Evidence
How FDA clears OTC and home-use IVDs via 510(k), De Novo, and CLIA-waiver, and the study designs behind them.
Device
FDA Evaluation of Reagent Stability for In Vitro Diagnostics: Shelf-Life Expectations in Guidance and 510(k) Precedent
FDA reagent stability requirements for IVDs: applicable standards, claim types, and how stability data are structured in 510(k) submissions.
Device
ISO 15223-1 Symbols on Medical Device Labels and IFU: FDA, EU MDR, and Health Canada Regulatory Requirements and Enforcement Trends
How FDA, EU MDR, and Health Canada regulate ISO 15223-1 symbols on device labels and IFU, with FDA enforcement examples.
Device
FDA and EU MDR Regulation of Medical Device Kits, Convenience Kits, and Procedure Packs
FDA and EU MDR requirements for device kits and procedure packs: definitions, 510(k) applicability, labeling, sterility, and combining cleared components.
Device
FDA Recalls and Safety Communications for Insulin Pumps and Infusion Components: Patterns and Key Issues
FDA recall patterns, failure modes, and safety communications for insulin pumps, infusion sets, and automated insulin delivery components.
Device
Human Factors Deficiencies in FDA Premarket Submissions: Recurring Patterns Across Device Types
The human factors and usability engineering gaps FDA most often cites in device premarket submissions, and how they vary by device type.
Device
How the TGA Regulates Software as a Medical Device (SaMD) in Australia
How Australia's TGA classifies and regulates SaMD, including clinical decision support software rules, excluded-software categories, and ARTG exemptions.
Device
FDA Expectations for Biocompatibility and Ethylene-Oxide Sterilization Residuals in Premarket Submissions
How FDA applies ISO 10993-1 biocompatibility evaluation and ISO 10993-7 ethylene-oxide residual limits in device premarket submissions.
Device
Recent FDA 510(k) Clearances for Patient-Monitoring Devices: Product Codes, Predicates, and Intended Uses
Recent FDA 510(k) clearances for patient-monitoring devices, grouped by product code, with the predicates cited and intended uses claimed.
Device
FDA Regulation of Post-Market Algorithm Changes: Predetermined Change Control Plans for AI/ML-Enabled Devices
How FDA's predetermined change control plans authorize post-market algorithm changes to AI/ML-enabled devices, with statutory basis, plan requirements, and recent authorizations.
Device
MDSAP Requirements: How One Audit Satisfies Regulators in the US, Canada, Japan, Australia, and Brazil
How MDSAP's single third-party QMS audit works and how the FDA, Health Canada, ANVISA, TGA, and Japan's MHLW each accept the result.
Device
FDA Medical Device Product Codes: Assignment and Responsibility
How FDA three-character device product codes are created and maintained by CDRH, and how to use them for predicate identification and classification strategy.
Device
Sampling Plans and Sample Size for Design V&V Under ISO 13485
FDA guidance and standards for statistically defensible sampling plans in device design verification and validation under ISO 13485:2016 clauses 7.3.6–7.3.7.
Device
FDA PMA and HDE Submission Changes Under QMSR: Draft Guidance
FDA's October 2025 draft guidance on QMS information in PMA and HDE submissions under QMSR, and how it differs from the 2003 predecessor.
Device
Panel-Track PMA Supplements: When FDA Waives Advisory Review
FDA has discretion to waive advisory committee referral for panel-track PMA supplements—the regulatory basis and how that discretion is applied.
Device
MDR Stage 1 Audit Preparation for Reusable Surgical Instruments
MDR requirements—QMS, technical documentation, clinical evaluation, PMS, UDI, reprocessing—for Class Ir reusable surgical instruments before Stage 1 audit.
Device
513(g) Request Content for a Dental Device Without a Predicate
Content required in a 513(g) Request for an early-stage dental device without a clear predicate, versus Q-Submissions and De Novo classification.
Device
Vendor-Neutral Radiology SaMD: FDA Clearances and Predicates
FDA-cleared radiology SaMD (codes LLZ, QIH, QAS, QFM) from sponsors independent of imaging hardware makers, with predicate and vendor-neutrality analysis.
Device
FDA Approved vs. Cleared vs. Registered vs. Listed: Definitions
Definitions, permitted use, and FDA enforcement history for four commonly confused regulatory status terms across drugs, devices, and biologics.
Device
Predicate Devices and the 510(k): Eligibility and Equivalence
How FDA defines predicate devices, what qualifies as a legally marketed predicate, and the decision logic behind substantial equivalence determinations.
Device
510(k), De Novo, or PMA: Which FDA Device Pathway Applies
Which FDA premarket pathway applies to a device, why class and predicate drive the decision, and what forces a device into De Novo or PMA.
Device
Medical Device Classes I, II, and III and Reclassification
How FDA assigns Class I, II, or III to a medical device type, what controls each class requires, and how reclassification works.
Device
Substantial Equivalence vs NSE: How FDA Decides 510(k)s
The statutory test FDA uses to clear or reject 510(k) devices, including the conditions that trigger a not substantially equivalent determination.
Device
FDA Pre-Submissions (Q-Subs): Feedback and Common Mistakes
What FDA Pre-Submissions are, what feedback sponsors receive, and the most common mistakes that make them less useful.
Device
Software as a Regulated Medical Device vs Wellness Product
How FDA and EU frameworks determine whether software is a regulated medical device or an exempt wellness product, based on intended use and risk.
Device
Design Control: FDA Quality System Requirements and Citations
Design control requirements under 21 CFR Part 820 and the inspection citations FDA most commonly issues against device manufacturers.
Device
ISO 13485 and the QMSR: FDA's New Quality System Regulation
FDA replaced 21 CFR Part 820 with the QMSR, incorporating ISO 13485:2016 by reference — covering what changed and what manufacturers must do.
Device
FDA's Four-Criteria Test for Clinical Decision Support Software
FDA's four-criteria test for CDS device status explained, with recent clearances and where the regulatory line has shifted under the 2026 guidance.
Device
FDA-Cleared Wearables and the General-Wellness Exemption
Which wearable and digital-health features FDA cleared as devices, and which claims drew warning letters for exceeding the general-wellness exemption.
Device
EU MDR vs. FDA: Medical Device Clinical Investigations
A side-by-side comparison of EU MDR and FDA device clinical investigation rules: authorization, clinical evaluation, informed consent, and safety reporting.
Device
Fitbit FDA Medical Device Authorizations: A Regulatory Overview
All FDA 510(k) and De Novo authorizations for Fitbit devices through February 2025, covering cleared indications, pathways, and device classifications.
Device
FDA Acceptance of Out-of-US RWE in De Novo Classifications
De Novo classifications where FDA accepted ex-US real-world evidence, characterized by registry, geography, sample size, and benefit-risk role.
Device
Point-of-Care Diagnostic Device Clinical Trials: Registry Review
Clinical trials of point-of-care diagnostic devices registered across CTIS, EudraCT, MHRA, SNCTP, and jRCT, by device type, indication, and study design.
Device
Energy-Based Medical Devices Cleared and Approved, 2023–2026
FDA-cleared and approved energy-based devices from 2023 through mid-2026, organized by modality across 510(k), De Novo, and PMA pathways.
AI & Technology
AI & Technology
AI and Machine Learning in GMP Drug Manufacturing: FDA and EU Regulatory Expectations
How FDA and EU regulators, through FDA's discussion paper, draft guidance and draft Annex 22, expect AI models in GMP manufacturing to be validated and governed.
AI & Technology
FDA Regulation of Generative AI and LLM-Enabled Clinical Software
How FDA's existing device framework, 520(o) software exclusions, and PCCPs apply to LLM-enabled clinical software, and whether any generative AI device has been authorized.
Combination Product
Combination Product
FDA Requests for Designation: How PMOA Reasoning Determines the Lead Center for Combination Products
How FDA's Office of Combination Products decides Requests for Designation, and how primary-mode-of-action reasoning assigned CDER, CDRH or CBER in published precedents.
Combination Product
FDA Postmarketing Safety Reporting for Combination Products Under 21 CFR Part 4 Subpart B
How 21 CFR Part 4 Subpart B sets postmarketing safety reporting duties for combination product applicants, and how FDA guidance and enforcement apply them.
Combination Product
FDA DMEPA Labeling Recommendations for Self-Injection Devices: IFU and Carton/Container Revisions in NDA and BLA Reviews
IFU and carton/container labeling revisions FDA's DMEPA has requested for autoinjectors, pens and prefilled syringes in NDA and BLA reviews, with product examples.
Combination Product
FDA Human Factors Validation for Autoinjectors and Pen Injectors: Caregivers, Pediatric Users, and Patients with Dexterity or Visual Impairment
How FDA reviewers assessed human factors validation for autoinjectors and pen injectors used by caregivers, children, and patients with dexterity or vision limitations.
Combination Product
FDA Review of Silicone Oil, Particles, and Container Compatibility for Biologics in Prefilled Syringes and Autoinjectors
How FDA reviewers assess silicone oil, subvisible particles, leachables, and container compatibility for biologics in prefilled syringes and autoinjectors in BLA reviews.
Combination Product
FDA Review of Needle Safety and Sharps-Injury-Prevention Features on Prefilled Syringes and Pen Needles
How FDA evaluates needle guards and safety pen needles across 510(k) clearances and combination product reviews of prefilled syringes and pen injectors.
Combination Product
On-Body Injector vs Autoinjector Device Problems and Adverse Events in FDA MAUDE for Biologic Delivery
The device problems and adverse events reported to FDA MAUDE for biologic on-body injectors, compared with autoinjectors, with failure modes and patient outcomes.
Combination Product
Container-Closure Integrity for Prefilled Syringes: FDA Review Expectations in NDAs and BLAs Since 2018
How FDA reviewers assessed prefilled syringe container-closure integrity in NDA and BLA reviews since 2018: test methods, sensitivity, shipping and shelf life.
Combination Product
FDA Reviewer Questions on On-Body Injectors and Large-Volume Wearable Injectors in NDA and BLA Reviews
Device questions FDA reviewers raised on on-body and wearable injectors, covering dose accuracy, adhesion, occlusion, human factors, and 21 CFR Part 4.
Combination Product
Emergency-Use Injectable Combination Products: FDA Approvals and Supporting Evidence
FDA approvals of epinephrine, naloxone, and glucagon autoinjectors — the pathways used and the PK bridging and human factors evidence behind each.
Combination Product
Clinical, Human-Factors, and Labeling Evidence Supporting Patient Self-Administration Claims for Injectable Drugs and Biologics: FDA and EMA/CHMP Requirements
What clinical, human-factors, and labeling evidence FDA and EMA/CHMP require to approve patient self-administration claims for injectable drugs and biologics.
Combination Product
Identifying and Justifying Critical Tasks in the Use-Related Risk Analysis for Autoinjectors and Pen Injectors
How FDA expects sponsors to derive, justify, and document critical tasks in the use-related risk analysis for autoinjectors and pen injectors.
Combination Product
Type II DMF and FDA AMT Designation for Multiple ADC Clients
How ADC linker suppliers use a Type II DMF and FDA AMT designation to confidentially support multiple client applications via one pre-vetted platform.
Combination Product
Autoinjector Use Errors vs. Device Defects: Evidence from MAUDE
MAUDE analysis distinguishing autoinjector use errors from confirmed device defects—needlestick, incomplete dose, premature activation, and wrong-end use.
Combination Product
Drug, Device, Biologic, or Combination Product: FDA Classifies
How FDA statutory definitions, the PMOA standard, and formal designation determine if your product is a drug, device, biologic, or combination product.
Combination Product
Extractables and Leachables in FDA Combination-Product Reviews
FDA's E&L data requests across recent injectable, biologic, and combination-product reviews—what was asked, why, and against what framework.
Combination Product
Delivery-Device Changes to Subcutaneous Combination Products
How FDA has weighed human-factors, use-related risk, and PK bridging evidence for device changes to approved subcutaneous combination products.
Combination Product
Combination Product Types: Four Categories Under 21 CFR 3.2(e)
FDA's four combination product types under 21 CFR 3.2(e), how OCP assigns lead-center jurisdiction, and why classification drives pathway and reporting.
Combination Product
FDA Autoinjector Testing Requests With Acceptable Responses
CDER information requests on prefilled autoinjector testing since 2022 where FDA explicitly recorded the applicant's response as acceptable.
Combination Product
FDA DMEPA URRA Revision Requirements in BLA/NDA Reviews
CDER and CBER review records from 2021–2026 show URRA revision requests are routine FDA human factors review outcomes, not exceptional occurrences.
Combination Product
Autoinjector and Prefilled Pen Usability Studies in EU CTIS
EU CTIS-registered trials incorporating actual-use or usability assessments for autoinjectors and prefilled pens, covering 23 qualifying protocols.
Combination Product
CDER Injectable Combination Product Deficiencies, 2024–2025
Recurring CDER CMC and device essential-performance deficiency themes from 2024–2025 NDA/BLA reviews of injectable drugs and delivery systems.
Combination Product
FDA ISO 11040 Prefilled-Syringe Testing on Autoinjectors
Whether FDA requires ISO 11040 prefilled-syringe tests on finished autoinjectors, and how ISO 11040/11608 scope boundaries apply to combination products.
Combination Product
FDA ISO 11608 Conformance for Prefilled Syringes in NDAs/BLAs
How FDA has applied ISO 11608 standards in NDA/BLA reviews for prefilled syringes and PFS/NSD combination products from 2021 through mid-2026.
Combination Product
FDA Information Requests on 21 CFR Part 4 Combination cGMP
FDA information requests to combination-product applicants on 21 CFR Part 4 cGMP, organized by QSR provision with application numbers and product names.
Combination Product
CDER Review Questions on Autoinjectors and Prefilled Pens
Device-related CDER deficiencies, information requests from BLA reviews since 2023 for autoinjector and prefilled pen products, excluding human factors/IFU
Combination Product
CDER BLA Supplement Type to Extend Autoinjector Shelf Life
Which BLA supplement type CDER requires to extend labeled shelf life for autoinjector or prefilled pen presentations, based on Drugs@FDA records from 2021–2026.
Combination Product
Real-Life Handling Studies for Autoinjectors and Pens, 2020–2026
Real-life patient handling and home-use studies cited in FDA and EMA approval packages for autoinjectors and prefilled pens, 2020–2026.
Biologic
Biologic
FDA Regulation of Exosome and Extracellular Vesicle Therapeutic Products
How FDA classifies exosome and EV products as biologics, what INDs must show on manufacturing and characterization, and FDA's enforcement record.
Biologic
Antibody Titers, Immunobridging and Correlates of Protection in FDA Approvals
How FDA has used antibody titers, immunobridging and correlates of protection to approve vaccines and biologics, and how CBER and CDER justified them.
Biologic
How FDA Assesses Anti-Drug Antibody Immunogenicity in BLA Reviews
How FDA reviewers evaluate anti-drug antibody assays, judge immunogenicity's clinical impact and set immunogenicity labeling and postmarketing requirements in BLA reviews.
Biologic
FDA Data Requirements for Strain-Change and Variant Updates to Influenza and COVID-19 Vaccines
What FDA requires for influenza strain-change and COVID-19 variant vaccine supplements, from CMC and nonclinical data to immunobridging and postmarketing studies.
Biologic
361 HCT/Ps vs. Section 351 Biologics: FDA's Regulatory Line and Enforcement Against Unapproved Regenerative Medicine Products
How FDA separates 361 HCT/Ps from section 351 biologics under 21 CFR 1271.10(a), and its untitled letters, warning letters, and court actions against unapproved products.
Biologic
FDA and EMA CMC Expectations for Co-Formulated Antibody and Protein Biologics
How FDA and EMA guidance and approved-product reviews set CMC expectations for co-formulated antibodies and proteins: identity, ratio control, potency, and stability.
Biologic
FDA Evaluation of Dystrophin Expression and Functional Endpoints in Duchenne Muscular Dystrophy
How FDA has weighed dystrophin surrogate endpoints against functional outcomes across DMD exon-skipping, gene therapy, and corticosteroid approvals and advisory committees.
Biologic
Cell Therapy Release Specifications Accepted by FDA in BLA Reviews
How FDA has handled viability, cell dose, identity and purity release specifications for licensed cell therapies, drawn from CBER BLA review documents.
Biologic
FDA and EMA Accepted Endpoints and Trial Designs for Complement Inhibitors in Paroxysmal Nocturnal Hemoglobinuria
Pivotal designs, comparators and primary endpoints FDA and EMA accepted for PNH complement inhibitors and eculizumab biosimilars, with points of regulatory friction.
Biologic
FDA Evaluation of Host Cell Protein and Residual DNA Controls in BLA Reviews for Monoclonal Antibodies and Recombinant Proteins
How FDA reviewers have assessed host cell protein and residual DNA limits, HCP assay coverage, and related postmarketing commitments in BLAs for therapeutic proteins.
Biologic
FDA Review of Viral Clearance and Adventitious Agent Control in Monoclonal Antibody BLAs Under ICH Q5A
How FDA reviewers assess viral clearance validation and adventitious agent control in mAb BLAs under ICH Q5A, and the deficiencies they most often cite.
Biologic
FDA Replication-Competent Virus Testing and Long-Term Follow-Up for Gene Therapy Products
How FDA sets RCR, RCL and RCA testing and long-term follow-up for gene therapies, in CBER guidance and in postmarketing requirements at BLA approval.
Biologic
Potency Assays in CAR-T and Cell Therapy BLAs: CBER Precedent and Review Deficiencies
Potency assays FDA accepted for licensed CAR-T and cell therapy BLAs, and the recurring potency deficiencies CBER reviewers raised.
Biologic
CBER Accelerated Approvals for Cell and Gene Therapies: Surrogate Endpoints, Confirmatory Requirements and Post-Approval Status
Every CBER accelerated approval for cell and gene therapies through September 2026: surrogate endpoints, confirmatory requirements, conversions, restrictions and withdrawals.
Biologic
Hidradenitis Suppurativa Approvals at FDA and EMA: HiSCR Response Definitions and Pain and PRO Labeling Claims
How FDA and EMA defined HiSCR50/HiSCR75 for Humira, Cosentyx and Bimzelx in hidradenitis suppurativa, and which pain and PRO claims reached each label.
Biologic
Patients vs. Healthy Volunteers in First-in-Human Trials of CAR-T and T-Cell Engagers for Autoimmune Disease
Whether first-in-human CAR-T and T-cell engager trials in lupus, myasthenia gravis and systemic sclerosis dosed patients or healthy volunteers, and what regulators said.
Biologic
First-in-Human Starting Doses for Immune-Cell-Depleting and T-Cell-Engaging Antibodies Outside Oncology
How sponsors set first-in-human doses for depleting and CD3-engaging antibodies outside oncology, and which dose anchors FDA and EMA accepted when a formal MABEL or NOAEL derivation was not in the licensure record.
Biologic
Early CAR-T and T-Cell Engager Trials in Autoimmune Disease: Where They Opened and Pre-Dosing Requirements
Where early CAR-T and T-cell engager trials in autoimmune disease opened across Germany, Australia, China and the US, and what each regulator expects before first dosing.
Biologic
CRS, ICANS, Hospitalization and Monitoring Requirements for CAR-T and T-Cell Engager Trials in Autoimmune Disease
What FDA, EMA and current trial protocols expect for CRS, ICANS, inpatient monitoring and long-term follow-up in autoimmune CAR-T and T-cell engager studies.
Biologic
FcRn Blocker US Labels Compared: Efgartigimod, Rozanolixizumab and Nipocalimab
A side-by-side comparison of the four FDA-approved FcRn blocker labels: indications, antibody-status limits, dosing, route and warnings.
Biologic
Primary Endpoints and Pivotal Trial Designs Behind FDA and EMA Approvals in gMG, CIDP and ITP
Primary endpoints, pivotal trial designs and reviewer commentary behind FDA and EMA approvals in generalized myasthenia gravis, CIDP and immune thrombocytopenia.
Biologic
FDA Preclinical Testing and Toxicity Endpoints for Large-Molecule Drugs, IND to BLA
FDA and ICH S6(R1) nonclinical expectations for mAbs and therapeutic proteins: species selection, repeat-dose toxicity, safety pharmacology, immunogenicity, and DART.
Biologic
FDA Handling of Bacterial Endotoxin Test Method Issues in NDA and BLA Reviews
How FDA has handled low endotoxin recovery, recombinant factor C, MAT, and endotoxin method-suitability gaps in NDA/BLA reviews, postmarketing commitments, and CRLs.
Biologic
FDA vs. EMA Manufacturing Controls And GMP For Cell And Gene Therapy At The IND/CTA Stage
How FDA and EU requirements for CGT manufacturing diverge at the IND and CTA stage — licensing, QP release, phase-appropriate GMP, and submission content.
Biologic
Post-Approval Formulation and Excipient Changes to Licensed Biologics: FDA Evidence Expectations Under ICH Q5E
What FDA has required for analytical, stability, and clinical comparability when a licensed biologic changes formulation or excipients after approval.
Biologic
EU Biosimilar Approval Requirements: Comparability Exercises, Clinical Data, and Tailored Development Programs
EMA and CHMP requirements for EU biosimilar approval: comparability exercises, clinical data expectations, and tailored development pathways.
Biologic
FDA Expectations for Allogeneic iPSC-Derived Cell Therapies: Tumorigenicity, Cell Banking, CMC, and Comparability
FDA's regulatory expectations for allogeneic iPSC-derived cell therapies across tumorigenicity testing, cell banking, CMC, and comparability.
Biologic
Nonclinical Safety for ADCs and Biologics When No Pharmacologically Relevant Animal Species Exists
FDA and ICH frameworks for nonclinical safety when no relevant animal species exists — surrogate molecules, transgenic models, and BLA precedents for ADCs and biologics.
Biologic
FDA Aggregation Control for Therapeutic Monoclonal Antibodies in BLA Reviews
FDA's BLA expectations for mAb aggregation control: specifications, characterization methods, and common CMC review deficiencies.
Biologic
FDA Regulation of Biologics Manufacturing: 21 CFR 600–610, BLA CMC Expectations, Pre-License Inspections, and Common Enforcement Findings
FDA biologics manufacturing rules: how 21 CFR 600–610, BLA CMC requirements, pre-license inspections, and common enforcement findings apply to biologics facilities.
Biologic
505(b)(2) Eligibility for Biologics: The Drug-Biologic Boundary and the Deemed-BLA Transition
Whether 505(b)(2) can be used for a biologic, how FDA draws the drug-biologic line for proteins, and what the deemed-BLA transition changed.
Biologic
FDA-Approved RSV Vaccines and Monoclonal Antibodies: Labeled Indications
The six FDA-licensed RSV products — three vaccines and three monoclonal antibodies — with their BLA numbers, approval dates, and labeled populations.
Biologic
Research-Grade Protein to cGMP-Compliant Clinical Product
Transitioning recombinant protein from bench reagent to GMP investigational product: cell bank qualification, quality systems, analytical validation, release.
Biologic
Juvenile Animal Toxicity Study Waivers for Monoclonal Antibodies
How to justify a juvenile animal study waiver for monoclonal antibodies under ICH S6(R1), iPSP requirements, and FDA's 2025 draft nonclinical guidance.
Biologic
FDA Bispecific Antibody Approval vs Monoclonal Antibodies
Key FDA requirements for bispecific antibody approval that go beyond what a conventional monoclonal antibody submission must address.
Biologic
Endotoxin and Product-Contact Buffer Controls in FDA BLAs
FDA expectations for endotoxin limit justification and product-contact buffer controls, drawn from CBER and CDER BLA review memos over the last five years.
Biologic
FDA Cell and Gene Therapy Approvals: The Evidence Behind Them
How recent FDA cell and gene therapy approvals have been supported, by modality, with representative pivotal evidence rather than a complete inventory.
Biologic
CQAs and Analytical Similarity in FDA 351(k) Biosimilars
How FDA evaluates CQA tiering, analytical methods, and similarity findings across approved 351(k) biosimilars, with examples.
Biologic
Dupixent (Dupilumab) FDA Labeling Changes, July 2022–2026
All FDA-approved labeling changes for Dupixent (dupilumab, BLA 761055) from July 2022 through July 2026, by supplement and approval date.
Biologic
FDA Controls for Retroviral/Lentiviral CAR-T Vectors
FDA controls required for BLA approval of retroviral and lentiviral CAR-T therapies: vector design, integration-site testing, and postmarket follow-up.
Biologic
EMA Nonclinical Toxicity Data for Polyvalent Immunoglobulins
Nonclinical toxicity data EMA accepts for human polyvalent immunoglobulins, with EPAR-based comparisons across Kiovig, Privigen, Hizentra, and HyQvia.
Biologic
FDA Review of In-Process Bioburden Limits in BLAs, 2021–2026
FDA microbiology findings on in-process bioburden limits, alert/action levels, hold-time studies, and method suitability across BLAs approved 2021–2026.